Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1genotyping in previous treated metastatic colorectal cancer patients:study protocol for a randomized controlled trial

BACKGROUND: Regorafenib is an oral multikinase inhibitor for metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidines, irinotecan, oxaliplatin, monoclonal antibodies targeting vascular endothelial growth factor, and monoclonal antibodies targeting epidermal growth factor recepto...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Cheng-Jen, Chang, Tsung-Kun, Tsai, Hsiang-Lin, Su, Wei-Chih, Huang, Ching-Wen, Yeh, Yung-Sung, Chang, Yu-Tang, Wang, Jaw-Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6923824/
https://www.ncbi.nlm.nih.gov/pubmed/31856912
http://dx.doi.org/10.1186/s13063-019-3917-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6923824/
https://www.ncbi.nlm.nih.gov/pubmed/31856912
http://dx.doi.org/10.1186/s13063-019-3917-z

Ejemplares similares